Telix to buy Germany’s ITM Isotope for $1.65B to expand radiopharma footprint

Arundhati Sarkar

• Australian biotechnology company Telix Pharmaceuticals (TLX) has agreed to acquire Germany's ITM Isotope in a $1.65B deal, the companies said on Monday, with the deal expected to strengthen Telix’s position as a vertically integrated radiopharmaceutical company with the capabilities

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.